Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Coverage Initiated by Analysts at Wells Fargo & Company

Wells Fargo & Company started coverage on shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) in a research note issued to investors on Wednesday, MarketBeat reports. The brokerage set an “overweight” rating and a $87.00 price target on the stock. Wells Fargo & Company‘s target price suggests a potential upside of 15.28% from the stock’s previous close.

A number of other research analysts have also weighed in on KNSA. JPMorgan Chase & Co. raised their price objective on Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Citigroup boosted their target price on Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. The Goldman Sachs Group increased their price target on Kiniksa Pharmaceuticals International from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Wedbush raised their price target on Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the company an “outperform” rating in a report on Wednesday, July 29th. Finally, Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 12th. Seven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $93.14.

Kiniksa Pharmaceuticals International Price Performance

Shares of KNSA stock traded down $0.26 during mid-day trading on Wednesday, hitting $75.47. The company had a trading volume of 17,851 shares, compared to its average volume of 682,761. Kiniksa Pharmaceuticals International has a 52-week low of $35.20 and a 52-week high of $82.94. The stock’s 50 day moving average price is $76.56 and its 200-day moving average price is $61.16. The company has a market capitalization of $5.89 billion, a P/E ratio of 77.47 and a beta of 0.09.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its earnings results on Tuesday, July 28th. The company reported $0.30 earnings per share for the quarter, meeting the consensus estimate of $0.30. The company had revenue of $243.60 million during the quarter, compared to analysts’ expectations of $226.49 million. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 13.65%. On average, equities research analysts expect that Kiniksa Pharmaceuticals International will post 1.37 earnings per share for the current year.

Insider Transactions at Kiniksa Pharmaceuticals International

In other news, CAO Michael Megna sold 4,600 shares of the business’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $80.30, for a total value of $369,380.00. Following the sale, the chief accounting officer directly owned 29,062 shares in the company, valued at $2,333,678.60. The trade was a 13.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director G. Bradley Cole sold 3,673 shares of the company’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $81.43, for a total transaction of $299,092.39. Following the sale, the director owned 11,672 shares in the company, valued at $950,450.96. This represents a 23.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 51.98% of the company’s stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Institutional investors have recently modified their holdings of the stock. Integrated Wealth Concepts LLC bought a new position in shares of Kiniksa Pharmaceuticals International during the 2nd quarter valued at approximately $177,000. Allworth Financial LP lifted its position in Kiniksa Pharmaceuticals International by 42.0% in the second quarter. Allworth Financial LP now owns 453 shares of the company’s stock worth $29,000 after buying an additional 134 shares during the last quarter. Arizona State Retirement System lifted its position in Kiniksa Pharmaceuticals International by 2.1% in the second quarter. Arizona State Retirement System now owns 10,132 shares of the company’s stock worth $648,000 after buying an additional 209 shares during the last quarter. Nykredit A S purchased a new position in Kiniksa Pharmaceuticals International during the second quarter worth $34,000. Finally, Corient Private Wealth LP boosted its stake in Kiniksa Pharmaceuticals International by 26.8% during the second quarter. Corient Private Wealth LP now owns 10,214 shares of the company’s stock worth $653,000 after buying an additional 2,158 shares during the period. 53.95% of the stock is owned by institutional investors.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc (NASDAQ: KNSA) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for patients with debilitating diseases, particularly conditions involving the immune system and inflammation. The company concentrates on areas of significant unmet medical need and uses biologic medicines and other targeted approaches in its research and development programs.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor.